Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.
The use of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a live vector for enterotoxigenic Escherichia coli (ETEC) antigens is reported. CVD 1203 alone or expressing colonization factor antigen fimbriae and CS3 fibrillae of ETEC was given to guinea pigs and mice, orogastrically (o.g.) or intranasally (i.n.). CVD 1203 given i.n. elicited high titers of antilipopolysaccharide (anti-LPS) immunoglobulin A (IgA) and was protective in guinea pigs against a homologous conjunctival challenge. Whereas a strong IgA response against colonization factor antigen CS3, and Shigella LPS was detected in tears and serum of guinea pigs after o.g. or i.n. immunization, the i.n. route elicited significantly higher antibody titers. A strong serum IgG response was also observed against the ETEC antigens, although no serum anti-LPS IgG response was detected. The immune response in mice followed a pattern similar to that in guinea pigs, and the difference between the responses after o.g. and i.n. administration was even more remarkable.
Noriega
F R
FR
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.
Losonsky
G
G
Wang
J Y
JY
Formal
S B
SB
Levine
M M
MM
D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase; D019883:Alkyl and Aryl Transferases; D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology*; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D004268:DNA-Binding Proteins / Q000235:genetics; D004333:Drug Administration Routes; D004405:Dysentery, Bacillary / Q000517:prevention & control*; D004926:Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000517:prevention & control*; D036781:Fimbriae Proteins; D005753:Gastric Mucosa / Q000276:immunology; D006168:Guinea Pigs; D007070:Immunoglobulin A / Q000032:analysis / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007159:Immunologic Tests; D051379:Mice; D009061:Mouth Mucosa / Q000276:immunology; D009297:Nasal Mucosa / Q000276:immunology; D017384:Sequence Deletion; D012763:Shigella flexneri / Q000235:genetics / Q000276:immunology*; D014157:Transcription Factors / Q000235:genetics; D014166:Transferases / Q000235:genetics; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D004268:DNA-Binding Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D014157:Transcription Factors; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; C022924:colonization factor antigens; C058483:virG protein, Shigella flexneri; D036781:Fimbriae Proteins; D014166:Transferases; D019883:Alkyl and Aryl Transferases; D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase